Adverse effects of androgen-deprivation therapy in prostate cancer and their management

被引：117

作者：

Rhee, Handoo ^{[1
,3
]}

Gunter, Jennifer H. ^{[3
]}

Heathcote, Peter ^{[1
,3
]}

Ho, Ken ^{[2
]}

Stricker, Phillip ^{[4
,5
]}

Corcoran, Niall M. ^{[6
]}

Nelson, Colleen C. ^{[3
]}

机构：

[1] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia

[2] Princess Alexandra Hosp, Ctr Hlth Res, Brisbane, Qld, Australia

[3] Queensland Univ Technol, Princess Alexandra Hosp, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia

[4] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia

[5] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia

[6] Epworth Healthcare, Epworth Prostate Ctr, Melbourne, Vic, Australia

来源：

BJU INTERNATIONAL | 2015年 / 115卷

关键词：

androgen-deprivation therapy; prostate cancer; adverse effect; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; METASTASIS-FREE SURVIVAL; BONE LOSS; CARDIOVASCULAR RISK; FRACTURE RISK; MEN; INTERMITTENT; OSTEOPOROSIS; DENOSUMAB;

D O I：

10.1111/bju.12964

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT). Patients and Methods All relevant medical literature on men with prostate cancer treated with ADT from 2005 to 2014, and older relevant papers, were reviewed. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document. Results There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis, to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimising the harm from ADT. Conclusions This review provides a series of practical recommendations to assist with managing the adverse effects of ADT.

引用

页码：3 / 13

页数：11

共 64 条

[1] The Challenges of Managing Urological Malignancy in the Elderly [J].

Abu-Ghanem, Yasmin ;

Dhesi, Jugdeep K. ;

Challacombe, Benjamin J. .

BJU INTERNATIONAL, 2014, 114 (01) :12-15

[2]

[Anonymous], CLIN PRACT GUID MAN

[3]

[Anonymous], 2012, Obesity and overweight

[4]

[Anonymous], NCCN GUID VERS 1 201

[5] Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States [J].

Beebe-Dimmer, Jennifer L. ;

Cetin, Karynsa ;

Shahinian, Vahakn ;

Morgenstern, Hal ;

Yee, Cecilia ;

Schwartz, Kendra L. ;

Acquavella, John .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (01) :70-78

[6] Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines [J].

Cheung, A. S. ;

Pattison, D. ;

Bretherton, I. ;

Hoermann, R. ;

Joon, D. Lim ;

Ho, E. ;

Jenkins, T. ;

Hamilton, E. J. ;

Bate, K. ;

Chan, I. ;

Zajac, J. D. ;

Grossmann, M. .

ANDROLOGY, 2013, 1 (04) :583-589

[7] Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial [J].

Cormie, Prue ;

Galvao, Daniel A. ;

Spry, Nigel ;

Joseph, David ;

Chee, Raphael ;

Taaffe, Dennis R. ;

Chambers, Suzanne K. ;

Newton, Robert U. .

BJU INTERNATIONAL, 2015, 115 (02) :256-266

[8] Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy [J].

Crook, Juanita M. ;

O'Callaghan, Christopher J. ;

Duncan, Graeme ;

Dearnaley, David P. ;

Higano, Celestia S. ;

Horwitz, Eric M. ;

Frymire, Eliot ;

Malone, Shawn ;

Chin, Joseph ;

Nabid, Abdenour ;

Warde, Padraig ;

Corbett, Thomas ;

Angyalfi, Steve ;

Goldenberg, S. Larry ;

Gospodarowicz, Mary K. ;

Saad, Fred ;

Logue, John P. ;

Hall, Emma ;

Schellhammer, Paul F. ;

Ding, Keyue ;

Klotz, Laurence .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (10) :895-903

[9] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[10]

de Leval Jean, 2002, Clin Prostate Cancer, V1, P163, DOI 10.3816/CGC.2002.n.018

← 1 2 3 4 5 6 7 →